Opthea Ltd (ASX: OPT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Opthea Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Opthea Ltd (ASX: OPT)
Latest News
Coronavirus News
Top broker tips Opthea shares as a strong buy during the coronavirus crisis
Share Market News
Why this ASX healthcare share has risen over 200% in the past year
Share Market News
3 ASX healthcare growth shares to add to your 2020 watchlist
Growth Shares
3 excellent ASX healthcare shares to bring your portfolio to life
⏸️ ASX Shares
Experts are tipping these healthcare shares for big things
Share Market News
Paradigm Biopharmaceuticals shares have skyrocketed. Should you invest?
Share Market News
Why this growing ASX healthcare company should be on everyone's watch lists
⏸️ ASX Shares
3 exciting mid cap ASX shares to buy for strong returns in the 2020s
Speculative
4 small cap ASX shares that could be stars of the future
Share Gainers
The Opthea share price is up 370% in 12 months: Can it go higher?
Growth Shares
3 ASX healthcare shares I want to buy and hold in the 2020s
Share Gainers
Why Domino's, Opthea, Orocobre, & PolyNovo shares are storming higher
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
OPT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Opthea Ltd
Opthea Limited (ASX: OPT) is a biopharmaceutical company specialising in the development of biological therapeutics for retinal eye diseases. The company is developing a novel therapy, OPT-302, designed to be used in combination with existing therapies. OPT-302, the company's leading drug candidate, has the potential to address wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in patients. It is currently at Phase 3 clinical trial stage.
OPT Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
22 Apr 2024 | $0.65 | $0.01 | 1.56% | 1,014,341 | $0.63 | $0.65 | $0.62 |
19 Apr 2024 | $0.64 | $0.01 | 1.59% | 585,166 | $0.65 | $0.65 | $0.61 |
18 Apr 2024 | $0.63 | $-0.02 | -3.10% | 2,272,452 | $0.65 | $0.66 | $0.62 |
17 Apr 2024 | $0.65 | $-0.02 | -3.03% | 206,743 | $0.66 | $0.67 | $0.64 |
16 Apr 2024 | $0.66 | $-0.03 | -4.35% | 599,410 | $0.68 | $0.68 | $0.65 |
15 Apr 2024 | $0.69 | $-0.03 | -4.17% | 451,013 | $0.71 | $0.72 | $0.69 |
12 Apr 2024 | $0.72 | $0.00 | 0.00% | 419,968 | $0.73 | $0.73 | $0.71 |
11 Apr 2024 | $0.72 | $0.01 | 1.40% | 341,966 | $0.72 | $0.73 | $0.71 |
10 Apr 2024 | $0.72 | $-0.04 | -5.33% | 384,802 | $0.75 | $0.75 | $0.72 |
09 Apr 2024 | $0.75 | $0.01 | 1.34% | 3,647,134 | $0.75 | $0.75 | $0.74 |
08 Apr 2024 | $0.75 | $0.01 | 1.36% | 954,484 | $0.75 | $0.75 | $0.75 |
05 Apr 2024 | $0.74 | $0.01 | 1.38% | 2,751,797 | $0.74 | $0.75 | $0.73 |
04 Apr 2024 | $0.73 | $-0.03 | -4.00% | 838,926 | $0.75 | $0.75 | $0.72 |
03 Apr 2024 | $0.75 | $0.00 | 0.00% | 923,401 | $0.75 | $0.76 | $0.72 |
02 Apr 2024 | $0.75 | $0.01 | 1.35% | 1,148,171 | $0.76 | $0.82 | $0.75 |
28 Mar 2024 | $0.74 | $0.00 | 0.00% | 3,013,374 | $0.76 | $0.79 | $0.74 |
27 Mar 2024 | $0.74 | $0.03 | 4.23% | 3,345,074 | $0.73 | $0.78 | $0.72 |
26 Mar 2024 | $0.71 | $0.02 | 2.88% | 581,362 | $0.72 | $0.72 | $0.70 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
01 Mar 2024 | Megan Baldwin | Sell | 987,723 | $543,247 |
As advised by the company. Sale of 987,723 ordinary shares to cover
personal tax obligations |
01 Mar 2024 | Megan Baldwin | Sell | 3,012,277 | $1,656,752 |
As advised by the company. Sale of 3,012,277 ordinary shares to cover
personal tax obligations |
21 Dec 2023 | Jeremy Levin | Issued | 3,000,000 | $1,410,000 |
Issue of options.
|
21 Dec 2023 | Anshul Thakral | Issued | 1,000,000 | $470,000 |
Issue of options.
|
21 Dec 2023 | Lawrence Gozlan | Issued | 500,000 | $235,000 |
Issue of options. As per announcement on 21-12-2023
|
21 Dec 2023 | Megan Baldwin | Issued | 3,000,000 | $1,410,000 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Lawrence Bernard Gozlan | Non-Executive Director | Jul 2020 |
Mr Gozlan, a biotechnology investor and advisor, is the Life Sciences Investment Manager at Jagen Pty Ltd, an international private investment organization. Mr Gozlan is also the Chief Investment Officer and Founder of Scientia Capital, a specialized global investment fund focused exclusively on life sciences. Scientia was founded to provide high level expertise and to manage investments for high-net-worth individuals, family offices and institutional investors wanting exposure to the life sciences industry. 20 Opthea Limited Prior to this, Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC ("the Queensland Investment Corporation"), an investment fund with over $60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking and gained senior corporate finance experience advising life science companies at Deloitte.
|
Dr Jeremy Levin | Non-Executive ChairmanNon-Executive Director | Oct 2020 |
Dr Levin served as the President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company. Dr. Levin held several roles at Bristol Myers Squibb Company, a publicly held pharmaceutical company, ultimately serving as the Senior Vice President of Strategy, Alliances and Transactions. Dr. Levin also served as a member of the executive committee at Bristol Myers Squibb Company.
|
Dr Julia Haller | Non-Executive Director | Jun 2021 |
Dr Haller has served as Ophthalmologist in Chief and William Tasman. ME Endowed Chair at Wills Eye Hospital in Philadelphia. She is Professor and Chair of the Department of Ophthalmology at the Sidney Kimmel Medical College at Thomas Jefferson University as well as a Director of Bristol Myers Squibb and Outlook Therapeutics. She is a member of the National Academy of Medicine, the Chair of the College of Physicians of Philadelphia, Chair of the Heed Ophthalmic Society, past president of the Women in Medicine Legacy Foundation, and serves on several prestigious boards including the board of the John Hopkins Medical and Surgical Association, the Association of University Professors of Ophthalmology, and the Society of Heed Fellows.
|
Dr Susan Orr | Non-Executive Director | Apr 2022 |
Dr Orr is an experienced medical and business leader with specialization in identifying, developing and commercializing ophthalmic therapeutic product candidates. Dr Orr currently serves as the Chief Medical Officer at Claris Biotherapeutics and is a member of the Retina Global Board of Directors. Before Claris, Dr Orr was the Chief Executive Officer at Notal Vision subsequent to joining the company as Chief Medical Officer. Dr Orr has spent more than 30 years in the field of ophthalmology that also includes ten years in private optometric practice and leadership roles at Alcon and Janssen spanning international development, global new product strategy, and business development and licensing. Dr Orr participated in multiple acquisitions including Durezol and Beovu and has been a Managing Partner at Fovenedeye Consulting.
|
Mr Quinton Oswald | Non-Executive Director | Apr 2022 |
Mr Oswald brings over 25 years of international general management experience, including onsite assignments in the US, Europe and South Africa. Most recently, he was the CEO of Notal Vision, a commercial stage ophthalmic home monitoring services provider with a focus on both wet and dry AMD. Prior to Notal Vision, he served as the CEO of Neurotech and, prior to that, as the CEO of SARcode Bioscience, where he was instrumental in the clinical development of lifitegrast ophthalmic solution 5% (Xiidra) for the treatment of dry eye disease, and its subsequent sale to Shire, PLC. Previously, he was Vice President and Business Unit Head for Genentech's tissue growth and repair business. During his tenure at Genentech, Mr Oswald oversaw the highly successful commercial launch of Lucentis (ranibizumab) for the treatment of wet AMD. Before Genentech, Mr. Oswald led the North American Ophthalmology business for Novartis, which, in conjunction with QLT, Inc., pioneered Visudyne.
|
Mr Anshul Thakral | Non-Executive Director | Jun 2023 |
Mr Thakral is Chief Executive Officer and Board Member of Launch Therapeutics, a clinical development company backed by funds managed by global investment firm Carlyle and its life sciences franchise, Abingworth. Mr Thakral has worked for over 20 years in the pharmaceutical and biotechnology industry and is an experienced executive, management consultant and entrepreneur. Mr Thakral was previously Chief Commercial Officer and Executive Vice President of Peri and Post-Approval Services at PPD, and prior to that was Global Head of PPD Biotech. Before PPD, Mr Thakral ran the global life sciences business unit at Gerson Lehrman Group and worked at McKinsey & Company as an associate principal in the health care practice, where he provided strategic advice to global pharmaceutical and biotechnology companies on growth, research and development, business development and commercialization. He currently serves on the boards of TriNetX, Saama Technologies, Orsini Specialty Pharmacy, is an Operating Executive at Carlyle and is a Venture Partner at Abingworth.
|
Mr Sujal Arun Shah | Non-Executive Director | Apr 2024 |
Mr Shah brings two decades of experience as a biopharmaceutical executive and strategic advisor to the Opthea Board. Most recently, Mr Shah served as President and Chief Executive Officer at CymaBay Therapeutics, a clinicalstage biopharmaceutical company developing innovative therapies for patients with liver and other chronic diseases. Mr Shah joined CymaBay as Chief Financial Officer, taking the company public in 2013. Prior to CymaBay, Mr Shah was a healthcare investment bankerfor Citigroup Inc. as well as Credit Suisse, where he wasresponsible for managing client relationships and executing strategic and financing related transactions for clients on life sciences. Mr Shah currently serves as Chairman of the Board of Tvardi Therapeutics and as a Director on the Board of Stratus Therapeutics.
|
Mrs Karen Adams | Company SecretaryVice President of Finance | Jun 2021 |
-
|
Dr Frederic Guerard | Chief Executive Officer | Oct 2023 |
-
|
Judith Robertson | Chief Commercial Officer |
-
|
|
Frederic Guerard | Chief Executive Officer |
-
|
|
Timothy Morris | Chief Financial Officer |
-
|
|
Joel Naor | Chief Medical Officer |
-
|
|
Karen Adams | Company SecretaryVice President of Finance |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Hsbc Custody Nominees (Australia) Limited | 113,819,968 | 24.36% |
Citicorp Nominees Pty Limited | 61,449,070 | 13.15% |
Usb Nominees Pty Ltd | 35,562,811 | 7.61% |
JP Morgan Nominees Australia Pty Limited | 34,576,016 | 7.40% |
Merrill Lynch (Australia) Nominees Pty Limited | 23,329,680 | 4.99% |
National Nominees Limited | 22,739,390 | 4.87% |
Bnp Paribas Noms Pty Ltd <Drp | 15,855,958 | 3.39% |
Jagen Pty Ltd | 11,581,484 | 2.48% |
Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 6,875,408 | 1.47% |
Hsbc Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 5,762,622 | 1.23% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 5,519,023 | 1.18% |
Ms Margaret Lynette Harvey | 5,268,323 | 1.13% |
Armada Trading Pty Limited | 5,005,806 | 1.07% |
Safo Trading Pty Ltd | 3,641,130 | 0.78% |
Gaja Holdings | 3,207,576 | 0.69% |
Safo Investments Pty Ltd <Safo Investments A/C> | 3,039,766 | 0.65% |
HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> | 3,000,000 | 0.64% |
Bilgola Nominees Pty Limited | 2,934,490 | 0.63% |
Suibian Trading Pty Ltd | 2,933,644 | 0.63% |
Sandhurst Trustees Ltd <Jmfg Consol A/C> | 2,561,995 | 0.55% |